📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Dr. Lal PathLabs Q4 Revenue Jumps 16.6% to ₹703 Cr; FY26 Normalized PAT Up 17.9%
Dr. Lal PathLabs reported its highest quarterly revenue growth in 16 quarters, with Q4 FY26 revenue rising 16.6% YoY to ₹703 crore. For the full year FY26, normalized PAT grew by 17.9% to ₹532 crore, supported by a 12.2% increase in total revenue. The company demonstrated strong volume momentum with sample counts increasing by 12.9% in Q4, while maintaining a robust ROCE of 44% excluding cash. Strategic expansion continued with the addition of 14 labs and over 1,100 collection centers during the fiscal year.
Key Highlights
Q4 FY26 revenue grew 16.6% YoY to ₹703 crore, marking the highest growth in 16 quarters.
Full-year FY26 normalized PAT increased by 17.9% to ₹532 crore with a stable 28.3% EBITDA margin.
Sample volumes grew 12.9% in Q4 FY26, reaching 23.6 million samples for the quarter.
SwasthFit (bundled offerings) contribution increased to 28% of revenue in Q4 FY26 compared to 26% last year.
Cash and cash equivalents strengthened to ₹1,526 crore as of March 31, 2026.
💼 Action for Investors
Investors should focus on the accelerating volume growth and successful penetration into Tier 3 and 4 markets. The strong cash position and stable margins provide a solid foundation for future organic and inorganic growth in the diagnostic space.
Loading analysis...
Dr. Lal PathLabs Recommends ₹4 Dividend, Acquires SDCPL, and Expands to Dubai
Dr. Lal PathLabs has announced its FY26 results along with a final dividend of ₹4 per share (40% of face value). The company is significantly expanding its footprint by acquiring 100% of Shahbazkers Diagnostic Centre and establishing a new wholly-owned subsidiary in Dubai, UAE. Leadership stability is ensured with the re-appointment of Executive Chairman Dr. Arvind Lal for another five-year term. Additionally, the company increased its paid-up capital through the allotment of 82,750 equity shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of ₹4 per equity share for the financial year ended March 31, 2026.
Approved the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL).
Announced international expansion through the incorporation of Dr. Lal PathLabs FZCO in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for five years starting April 1, 2027.
Allotted 82,750 equity shares under ESOP 2022, bringing total paid-up equity capital to ₹167.64 crore.
💼 Action for Investors
Investors should take note of the June 26, 2026, record date for the ₹4 dividend and the company's aggressive inorganic growth strategy. The entry into the Dubai market and domestic acquisitions suggest a strong growth trajectory for the coming years.
Loading analysis...
Dr. Lal Path Labs Recommends ₹4 Dividend, Announces Acquisition and Dubai Expansion
Dr. Lal Path Labs reported its FY26 results and recommended a final dividend of ₹4 per share, with a record date of June 26, 2026. The company is expanding its footprint through the 100% acquisition of Shahbazkers Diagnostic Centre and the incorporation of a new subsidiary in Dubai. Leadership stability is maintained with the 5-year re-appointment of Executive Chairman Dr. Arvind Lal. Additionally, the company allotted 82,750 shares under its ESOP scheme, increasing the total paid-up equity shares to 16.76 crore.
Key Highlights
Recommended a final dividend of ₹4 per equity share (40% of face value) for the financial year ended March 31, 2026.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited to strengthen domestic presence.
Announced international expansion with the incorporation of a wholly-owned subsidiary in Dubai, UAE.
Re-appointed Executive Chairman Dr. Arvind Lal for a 5-year term starting April 2027.
Allotted 82,750 equity shares under ESOP 2022, bringing total paid-up capital to ₹167.64 crore.
💼 Action for Investors
The combination of a dividend payout and strategic acquisitions/international expansion makes this a positive update for long-term investors. Monitor the integration of the new acquisition and the progress of the Dubai subsidiary.
Loading analysis...
Dr. Lal PathLabs to Acquire Shahbazkers Diagnostic and Recommends INR 4 Dividend
Dr. Lal PathLabs has approved the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited, strengthening its domestic presence. The board also recommended a final dividend of INR 4 per equity share for FY26, with a record date set for June 26, 2026. Strategically, the company is expanding internationally by incorporating a new subsidiary in Dubai, UAE. Furthermore, the leadership team remains stable with the re-appointment of Dr. Arvind Lal as Executive Chairman for a five-year term starting in 2027.
Key Highlights
Acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL).
Recommendation of a final dividend of INR 4 per equity share (40% of face value).
International expansion via incorporation of Dr. Lal PathLabs FZCO in Dubai, UAE.
Allotment of 82,750 equity shares under ESOP 2022, increasing paid-up capital to INR 167.64 crore.
Re-appointment of Dr. Arvind Lal as Executive Chairman for 5 years effective April 2027.
💼 Action for Investors
Investors should look favorably upon the inorganic growth through acquisition and the strategic entry into the UAE market. The dividend recommendation and management continuity provide additional confidence in the company's long-term stability.
Loading analysis...
Dr. Lal PathLabs Declares ₹4 Dividend, Acquires SDCPL, and Expands to Dubai
Dr. Lal PathLabs has announced its audited FY26 financial results and recommended a final dividend of ₹4 per share (40% of face value). The company is pursuing aggressive growth by acquiring a 100% stake in Shahbazkers Diagnostic Centre (SDCPL) and establishing a new subsidiary in Dubai, UAE. Leadership stability is reinforced with the re-appointment of Dr. Arvind Lal as Executive Chairman for a five-year term starting April 2027. Furthermore, the company expanded its equity base by allotting 82,750 shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of ₹4 per equity share for FY26, with a record date of June 26, 2026.
Approved the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL).
Incorporating a new wholly owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, for international expansion.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for 5 years effective April 1, 2027.
Allotted 82,750 equity shares under ESOP 2022, increasing paid-up capital to ₹167.64 crore.
💼 Action for Investors
The acquisition and international expansion into Dubai are significant growth catalysts that investors should monitor closely. The steady dividend and leadership continuity make this a positive development for long-term shareholders.
Loading analysis...
Dr. Lal PathLabs Recommends INR 4 Dividend, Acquires Shahbazkers, and Expands to Dubai
Dr. Lal PathLabs has announced a final dividend of INR 4 per share for FY26, with a record date set for June 26, 2026. The company is scaling its operations through the 100% acquisition of Shahbazkers Diagnostic Centre and a strategic entry into the UAE market with a new Dubai-based subsidiary. Leadership continuity is secured with the 5-year re-appointment of Executive Chairman Brig. Dr. Arvind Lal. Additionally, the company expanded its senior management team and increased its paid-up capital through ESOP allotments.
Key Highlights
Recommended a final dividend of INR 4 per equity share (40% of face value) for the financial year 2025-26.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited to strengthen domestic presence.
Announced international expansion with the incorporation of a Wholly Owned Subsidiary in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for a 5-year term starting April 2027.
Allotted 82,750 equity shares under ESOP 2022, increasing paid-up capital to INR 167.64 crore.
💼 Action for Investors
Investors should benefit from the steady dividend payout and monitor the execution of the Dubai expansion and the integration of the new acquisition. The long-term leadership extension provides stability for the company's growth trajectory.
Loading analysis...
Dr. Lal Path Labs FY26: INR 4 Dividend, 100% Acquisition, and UAE Expansion
Dr. Lal Path Labs reported its FY26 audited results alongside several strategic growth initiatives, including a final dividend of INR 4 per share. The company announced the 100% acquisition of Shahbazkers Diagnostic Centre to bolster its domestic footprint and is expanding internationally with a new subsidiary in Dubai, UAE. Leadership continuity is secured with the re-appointment of Dr. Arvind Lal as Executive Chairman for a five-year term starting in 2027. Additionally, the company strengthened its senior management team and completed a minor equity allotment under its ESOP scheme.
Key Highlights
Recommended a final dividend of INR 4 per equity share (40% of face value) for FY26.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL).
Announced international expansion via a new wholly-owned subsidiary in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for 5 years effective April 1, 2027.
Allotted 82,750 equity shares under ESOP 2022, increasing paid-up capital to INR 167.64 crore.
💼 Action for Investors
Investors should view the combination of domestic M&A and international expansion as a strong growth signal for the diagnostic major. The dividend and leadership continuity provide additional stability for long-term shareholders.
Loading analysis...
Dr. Lal PathLabs FY26: ₹4 Dividend, 100% Acquisition of Shahbazkers, and Dubai Expansion
Dr. Lal Path Labs has announced its audited FY26 financial results alongside a recommended final dividend of ₹4 per share. The company is pursuing aggressive growth through the 100% acquisition of Shahbazkers Diagnostic Centre and the establishment of a new subsidiary in Dubai, UAE. Leadership continuity is secured with the five-year re-appointment of Executive Chairman Dr. Arvind Lal. Additionally, the company allotted 82,750 equity shares under its ESOP scheme, marginally increasing the total paid-up capital to ₹167.64 crore.
Key Highlights
Recommended a final dividend of ₹4 per equity share (40% of face value) for FY26 with a record date of June 26, 2026.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited to expand domestic footprint.
Authorized incorporation of a wholly-owned subsidiary in Dubai, UAE, to facilitate international expansion.
Allotted 82,750 equity shares under ESOP 2022, bringing total paid-up equity capital to ₹167.64 crore.
Re-appointed Hony. Brig. Dr. Arvind Lal as Executive Chairman for a five-year term starting April 2027.
💼 Action for Investors
Investors should view the dual strategy of domestic acquisition and international expansion as strong growth drivers. The consistent dividend and leadership stability further support a positive long-term outlook for the stock.
Loading analysis...
Dr. Lal PathLabs Recommends INR 4 Dividend, Acquires Shahbazkers, and Expands to Dubai
Dr. Lal PathLabs has recommended a final dividend of INR 4 per share for FY26, with the record date set for June 26, 2026. Strategically, the company is acquiring 100% of Shahbazkers Diagnostic Centre and expanding its footprint into the UAE by incorporating a new subsidiary in Dubai. The board also ensured leadership continuity by re-appointing Dr. Arvind Lal as Executive Chairman for another five-year term starting April 2027. Furthermore, 82,750 shares were allotted under the ESOP scheme, slightly increasing the total paid-up capital to INR 167.64 crore.
Key Highlights
Recommended a final dividend of INR 4 per equity share (40% of face value) for FY26.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited to strengthen domestic presence.
Announced international expansion via the incorporation of a wholly owned subsidiary in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for a 5-year term starting April 2027.
Allotted 82,750 equity shares under ESOP 2022, increasing paid-up capital to INR 167.64 crore.
💼 Action for Investors
Investors should look favorably upon the dual strategy of domestic acquisition and international expansion into the UAE. The dividend and leadership continuity provide additional stability for long-term shareholders.
Loading analysis...
Dr. Lal PathLabs Approves INR 4 Dividend, 100% Acquisition of SDCPL, and Dubai Expansion
Dr. Lal PathLabs has announced a multi-pronged growth strategy alongside its FY26 results, including a final dividend of INR 4 per share. The company is set to acquire 100% of Shahbazkers Diagnostic Centre (SDCPL) and is expanding internationally by incorporating a new subsidiary in Dubai, UAE. Management stability is reinforced with the five-year re-appointment of Executive Chairman Dr. Arvind Lal. Furthermore, the company increased its paid-up capital to INR 167.64 crore following an ESOP allotment of 82,750 shares.
Key Highlights
Recommended a final dividend of INR 4 per equity share (40% of face value) for FY26 with a record date of June 26, 2026.
Approved the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) to strengthen domestic presence.
Announced international expansion via the incorporation of a wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for a five-year term commencing April 1, 2027.
Allotted 82,750 equity shares under the ESOP 2022 scheme, increasing the total paid-up equity share capital.
💼 Action for Investors
Investors should look favorably upon the dual strategy of domestic acquisition and international expansion into the Middle East. The dividend and management continuity provide additional confidence in the company's long-term growth trajectory.
Loading analysis...
Dr. Lal PathLabs Recommends ₹4 Final Dividend and Announces 100% Acquisition of SDCPL
Dr. Lal PathLabs has recommended a final dividend of ₹4 per equity share for FY 2025-26, with a record date set for June 26, 2026. Alongside the dividend, the company announced a 100% acquisition of Shahbazkers Diagnostic Centre and a strategic international expansion into Dubai, UAE. The board also ensured leadership continuity by re-appointing Dr. Arvind Lal as Executive Chairman for a five-year term starting in 2027. Additionally, the company's paid-up capital increased slightly following the allotment of 82,750 shares under its ESOP plan.
Key Highlights
Recommended a final dividend of ₹4 per equity share (40% of face value) for FY26.
Approved 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL).
Announced international expansion via a new wholly-owned subsidiary in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for 5 years effective April 2027.
Paid-up equity share capital increased to ₹167.64 crore following allotment of 82,750 ESOP shares.
💼 Action for Investors
Investors should maintain their positions to benefit from the upcoming dividend and monitor the integration of the new acquisition and the progress of the Dubai expansion. The long-term leadership stability is a positive indicator for future growth.
Loading analysis...
Dr. Lal PathLabs: INR 4 Dividend, 100% SDCPL Acquisition, and Dubai Expansion Announced
Dr. Lal PathLabs has announced its financial results for FY26 along with a final dividend of INR 4 per equity share, with the record date set for June 26, 2026. The company is aggressively pursuing growth through the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) and a new international expansion into Dubai, UAE. Leadership stability is ensured with the re-appointment of Executive Chairman Dr. Arvind Lal for a five-year term starting April 2027. Additionally, the company expanded its equity base by allotting 82,750 shares under its ESOP scheme.
Key Highlights
Recommended a final dividend of INR 4 per equity share (40% of face value) for FY ended March 31, 2026.
Approved the 100% acquisition of Shahbazkers Diagnostic Centre Private Limited (SDCPL) to become a wholly owned subsidiary.
Announced international expansion via the incorporation of a wholly owned subsidiary in Dubai, UAE.
Re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for a 5-year term starting April 1, 2027.
Allotted 82,750 equity shares under ESOP 2022, increasing paid-up capital to INR 167.64 crore.
💼 Action for Investors
Investors should view the combination of domestic M&A and international expansion as a strong growth signal for the company. The dividend payout and leadership continuity further support a positive long-term outlook for the stock.
Loading analysis...
Dr. Lal Path Labs Credit Rating Upgraded to CARE AA+; Stable from CARE AA
CARE Ratings has upgraded the issuer rating of Dr. Lal Path Labs from 'CARE AA; Stable' to 'CARE AA+; Stable'. The upgrade is based on the company's robust operational and financial performance reported in the FY25 audited results and 9MFY26 un-audited figures. This improvement in credit profile indicates a high degree of safety regarding financial obligations and reflects the company's strong market position. A higher rating can potentially lower future cost of capital and reinforces investor confidence in the management's financial discipline.
Key Highlights
Issuer rating upgraded to CARE AA+; Stable from CARE AA; Stable by CARE Ratings.
Rating action driven by strong financial performance in FY25 and 9MFY26.
The upgrade reflects improved creditworthiness and a high degree of safety for debt servicing.
The 'Stable' outlook indicates expected maintenance of the current financial profile in the medium term.
💼 Action for Investors
This upgrade confirms the company's financial strength and low-risk profile; long-term investors should remain positive on the stock as it reflects fundamental stability.
Loading analysis...
Dr. Lal PathLabs Q3 Revenue up 10.6% to Rs 660 Cr; Declares Rs 3.5 Dividend
Dr. Lal PathLabs reported a steady 10.6% YoY revenue growth for Q3 FY26, reaching Rs 660 Cr. While operational EBITDA (before exceptional items) grew strongly by 16.3% with margins expanding to 27.2%, the bottom line was impacted by a one-time exceptional charge of Rs 30.1 Cr related to new labour codes. Consequently, reported PAT declined 6.8% YoY to Rs 91 Cr. The company maintains a robust cash position of Rs 1,411 Cr and declared an interim dividend of Rs 3.5 per share.
Key Highlights
Revenue grew 10.6% YoY to Rs 660 Cr in Q3 FY26, with 9M revenue up 10.8% to Rs 2,060 Cr.
EBITDA before exceptional items rose 16.3% YoY to Rs 179 Cr, with margins improving to 27.2% from 25.8%.
Reported PAT fell 6.8% YoY to Rs 91 Cr due to a Rs 30.1 Cr one-time exceptional impact from new Labour Codes.
Strong liquidity position with cash and bank balances of Rs 1,411 Cr as of December 31, 2025.
Board declared an interim dividend of Rs 3.5 per share for the quarter.
💼 Action for Investors
Investors should focus on the healthy 16.3% growth in operational EBITDA and margin expansion, as the PAT decline is primarily due to a non-recurring exceptional item. The company's strong cash reserves and consistent dividend payout reflect financial stability.
Loading analysis...
Dr. Lal PathLabs Q3 Revenue Up 10.6% to ₹660 Cr; PAT Impacted by ₹30 Cr Exceptional Item
Dr. Lal PathLabs reported a steady 10.6% YoY revenue growth in Q3 FY26, reaching ₹660 crore, primarily driven by a 7.8% increase in sample volumes. While EBITDA (pre-exceptional) grew strongly by 16.3% to ₹179 crore with margins expanding to 27.2%, the reported PAT declined 6.8% YoY to ₹91 crore. This decline was due to a one-time exceptional charge of ₹30.1 crore related to the impact of new Labour Codes. The company continues to see strong traction in its Swasthfit wellness segment, which now contributes 26% of total revenue.
Key Highlights
Q3 FY26 Revenue grew 10.6% YoY to ₹660 crore, with 9M FY26 revenue crossing ₹2,060 crore.
EBITDA before exceptional items rose 16.3% to ₹179 crore, with margins improving to 27.2% from 25.8% YoY.
Reported PAT fell 6.8% to ₹91 crore following a ₹30.1 crore one-time provision for Labour Codes.
Sample volumes increased by 7.8% to 7.1 million, while patient volumes grew by 3% to 22.2 million in Q3.
Swasthfit wellness program contribution increased to 26% of revenue, up from 23% in the same quarter last year.
💼 Action for Investors
Investors should focus on the robust 16.3% EBITDA growth and margin expansion, as the PAT decline is purely due to a one-time non-operational exceptional item. The steady volume growth and increasing share of high-margin wellness packages (Swasthfit) remain positive long-term indicators.
Loading analysis...
Dr. Lal Path Labs Q3 Revenue Up 10.6% YoY; Declares INR 3.5 Interim Dividend
Dr. Lal Path Labs reported a 10.6% YoY growth in revenue from operations to INR 6,598 million for Q3 FY26. While operating profit before exceptional items grew to INR 1,544 million, the net profit saw a slight decline to INR 914 million due to a INR 301 million exceptional charge related to labor codes. The company declared its third interim dividend of INR 3.5 per share with a record date of February 5, 2026. Additionally, the board approved the allotment of 4,000 shares under the ESOP scheme.
Key Highlights
Revenue from operations grew 10.6% YoY to INR 6,598 million in Q3 FY26.
Profit before tax and exceptional items stood at INR 1,544 million, up from INR 1,383 million YoY.
Net profit after tax was impacted by a INR 301 million exceptional item related to labor codes, ending at INR 914 million.
Declared a 3rd interim dividend of INR 3.5 per share (35% of face value) with a record date of Feb 5, 2026.
Paid-up equity share capital increased to INR 1,675.55 million following ESOP allotment of 4,000 shares.
💼 Action for Investors
Investors should monitor the impact of the labor code provision on future margins and track volume growth in the core diagnostic business. The dividend provides a steady yield, but the stock's reaction will depend on management's commentary regarding the exceptional cost.
Loading analysis...
Dr. Lal PathLabs Q3 Results: Revenue Up 10.5%, ₹3.5 Interim Dividend Declared
Dr. Lal PathLabs reported a 10.5% YoY increase in revenue from operations to ₹6,598 million for Q3 FY26. However, net profit attributable to owners declined by 6.4% YoY to ₹905 million, largely due to a ₹301 million exceptional item related to the impact of new labour codes. The Board has declared a third interim dividend of ₹3.5 per share, with the record date set for February 5, 2026. Additionally, the company expanded its equity base slightly by allotting 4,000 shares under its ESOP 2010 plan.
Key Highlights
Revenue from operations grew 10.5% YoY to ₹6,598 million in Q3 FY26.
Net profit for the quarter stood at ₹905 million, down from ₹967 million in the previous year's corresponding quarter.
Declared a 3rd interim dividend of ₹3.5 per equity share (35% of face value) for FY 2025-26.
Reported a one-time exceptional expense of ₹301 million due to the impact of new Labour codes.
Allotted 4,000 equity shares under ESOP 2010, increasing total paid-up equity to 16,75,55,020 shares.
💼 Action for Investors
Investors should focus on the underlying revenue growth while noting that the profit dip was primarily driven by a one-time exceptional charge. The consistent dividend payout reflects a healthy cash position, making it a hold for long-term investors.
Loading analysis...
Dr. Lal PathLabs Q3 Revenue Up 10.5% to ₹6,598M; Declares ₹3.5 Interim Dividend
Dr. Lal PathLabs reported a 10.5% YoY growth in revenue from operations, reaching INR 6,598 million for the quarter ended December 31, 2025. While operational profit before exceptional items grew by 11.6% YoY to INR 1,544 million, the net profit (PAT) declined by 6.8% to INR 914 million due to a one-time exceptional charge of INR 301 million related to labor codes. The company declared its third interim dividend of INR 3.5 per share for FY 2025-26, with a record date of February 5, 2026. Additionally, the board approved the allotment of 4,000 equity shares under the ESOP 2010 plan.
Key Highlights
Revenue from operations grew 10.5% YoY to INR 6,598 million in Q3 FY26.
Profit before tax and exceptional items increased by 11.6% YoY to INR 1,544 million.
Net Profit (PAT) stood at INR 914 million, impacted by a one-time exceptional labor code cost of INR 301 million.
Declared a 3rd interim dividend of INR 3.5 per share (35% of face value) with a record date of Feb 5, 2026.
Nine-month (9M FY26) revenue reached INR 20,602 million, up from INR 18,588 million in the previous year.
💼 Action for Investors
Investors should focus on the steady 10.5% top-line growth and operational performance, as the PAT decline is primarily due to a non-recurring exceptional item. The consistent dividend payout remains a positive signal for long-term shareholders.
Loading analysis...
Dr. Lal PathLabs Declares ₹3.5 Interim Dividend; Q3 Revenue Grows 10.6% YoY
Dr. Lal PathLabs has declared its third interim dividend of ₹3.5 per share for FY 2025-26, with the record date set for February 5, 2026. The company reported a 10.6% YoY increase in Q3 revenue to ₹6,598 million, though net profit for the quarter dipped to ₹914 million from ₹981 million in the previous year. This profit decline was primarily due to a one-time exceptional item of ₹301 million related to the impact of new labor codes. For the nine-month period, the company maintains a healthy growth trajectory with PAT rising 12.1% to ₹3,776 million.
Key Highlights
Declared 3rd interim dividend of ₹3.5 per equity share (35% of face value).
Q3 FY26 revenue from operations rose 10.6% YoY to ₹6,598 million.
Net profit for the quarter stood at ₹914 million, impacted by a ₹301 million exceptional charge.
9M FY26 revenue reached ₹20,602 million compared to ₹18,588 million in the previous year.
Record date for dividend eligibility is February 5, 2026, with payment within 30 days.
💼 Action for Investors
Investors should view the profit dip as a one-time accounting adjustment rather than a business slowdown, given the double-digit revenue growth. The consistent dividend payout remains a positive sign for long-term income-seeking shareholders.
Loading analysis...
Dr. Lal PathLabs Q3 Revenue Grows 10.6% YoY to ₹6,598M; Declares ₹3.5 Interim Dividend
Dr. Lal PathLabs reported a 10.6% YoY increase in consolidated revenue for Q3 FY26, reaching INR 6,598 million. However, net profit for the quarter declined to INR 914 million from INR 981 million in the previous year, largely due to a one-time exceptional expense of INR 301 million related to labor code impacts. The company has declared a third interim dividend of INR 3.5 per share, maintaining its commitment to shareholder returns. While top-line growth remains healthy, margins were sequentially lower compared to the preceding quarter.
Key Highlights
Revenue from operations increased 10.6% YoY to INR 6,598 million in Q3 FY26.
Net profit (PAT) stood at INR 914 million, down from INR 981 million YoY due to a ₹301 million exceptional item.
Declared a 3rd interim dividend of INR 3.5 per equity share with a record date of February 5, 2026.
Total expenses rose to INR 5,298 million, driven by higher employee benefits and collection center fees.
Basic EPS for the quarter was INR 5.42, compared to INR 5.80 in the corresponding quarter of the previous year.
💼 Action for Investors
Investors should focus on the resilient 10% revenue growth while monitoring the impact of rising operational costs on margins. The dividend payout provides a steady yield, but the sequential dip in performance suggests a cautious watch on volume growth in the coming quarters.